Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
May 23, 2017

ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation as part of a panel on biotechnology at the Mauldin Economics’ Strategic Investment Conference on Wednesday, May 24 at 3:20pm EDT at the Omni Orlando Resort in Florida.

In his presentation, "Emerging Trends in Regenerative Medicine and Aging,” Dr. West will provide an update on product development by the BioTime group of companies, focusing on the strategy of transplanting young healthy cells into tissues afflicted with age-related degenerative disease. He will also discuss new products planned for development at BioTime'srecently-announced new subsidiary, AgeX Therapeutics.

More information about Mauldin Economics’ Strategic Investment Conference can be found here.

About BioTime

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Our clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of our cell delivery platform is its HyStem® cell and drug delivery matrix technology. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. We also have significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte Corporation (“OncoCyte”), which we founded and which, until recently, were our majority-owned consolidated subsidiaries.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:


Source: BioTime, Inc.

Investor Contact
EVC Group, Inc.
Michael Polyviou, 212-850-6020
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890